Piper Sandler last night upgraded Sutro Biopharma (STRO) to Overweight from Neutral with an unchanged price target of $2. The company plans to file three new drug applications on next-generation antibody-drug conjugates over the next three years, the analyst tells investors in a research note. The firm says Sutro ended Q1 with cash of $249M to fund operations into 2027 and currently trades at a negative $181M enterprise value. Piper sees an attractive valuation at current share levels.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO: